Vaxart (VXRT) Expected to Announce Earnings on Thursday

Vaxart (NASDAQ:VXRT) is projected to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Vaxart (NASDAQ:VXRT) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). Vaxart had a negative net margin of 122.63% and a negative return on equity of 91.89%. The company had revenue of $20.88 million during the quarter, compared to analysts’ expectations of $2.85 million. On average, analysts expect Vaxart to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vaxart Price Performance

VXRT stock opened at $0.40 on Thursday. Vaxart has a 52-week low of $0.26 and a 52-week high of $1.07. The company has a 50-day moving average of $0.45 and a two-hundred day moving average of $0.49. The stock has a market capitalization of $91.57 million, a price-to-earnings ratio of -1.48 and a beta of 1.12.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Vaxart to a “hold” rating in a report on Thursday, May 22nd.

Insider Activity at Vaxart

In related news, insider Steven Lo acquired 100,000 shares of the business’s stock in a transaction dated Monday, May 19th. The stock was acquired at an average price of $0.49 per share, with a total value of $49,000.00. Following the completion of the transaction, the insider owned 100,000 shares of the company’s stock, valued at approximately $49,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in VXRT. Goldman Sachs Group Inc. acquired a new position in shares of Vaxart during the first quarter valued at about $31,000. Invesco Ltd. raised its position in shares of Vaxart by 93.1% during the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 70,568 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its position in shares of Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 478,111 shares during the last quarter. Institutional investors and hedge funds own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.